CEMI:NSD-Chembio Diagnostics Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 2.59

Change

-0.08 (-3.00)%

Market Cap

USD 0.08B

Volume

1.33M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

-0.38 (-0.09%)

USD67.80B 82.96 58.15
IDXX IDEXX Laboratories Inc

-2.94 (-0.43%)

USD58.07B 81.38 59.21
DXCM DexCom Inc

-11.99 (-2.09%)

USD55.41B 107.29 123.24
ICLR ICON Public Limited Company

+1.58 (+0.56%)

USD22.43B 41.05 39.32
EXAS Exact Sciences Corporation

-2.20 (-2.24%)

USD16.89B N/A N/A
GH Guardant Health Inc

-0.92 (-0.71%)

USD13.30B N/A N/A
NTRA Natera Inc

-5.42 (-4.39%)

USD11.59B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
SYNH Syneos Health Inc

+0.29 (+0.30%)

USD9.97B 43.01 22.18
MEDP Medpace Holdings Inc

+2.97 (+1.52%)

USD6.99B 42.09 30.33

ETFs Containing CEMI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.47% 12% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.47% 12% F 8% F
Trailing 12 Months  
Capital Gain -44.66% 5% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.66% 5% F 6% F
Trailing 5 Years  
Capital Gain -63.31% 36% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.31% 36% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -1.01% 21% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.01% 20% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 42.60% 70% C- 43% F
Risk Adjusted Return -2.37% 23% F 18% F
Market Capitalization 0.08B 21% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.97 47% F 29% F
Price / Cash Flow Ratio -4.05 56% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -97.48% 20% F 19% F
Return on Invested Capital -48.95% 40% F 17% F
Return on Assets -21.58% 31% F 17% F
Debt to Equity Ratio 65.46% 27% F 32% F
Technical Ratios  
Short Ratio 0.35 98% A+ 89% B+
Short Percent 11.67% 14% F 13% F
Beta 1.89 15% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector